CD274 and non-small cell lung carcinoma: In the KEYNOTE‐042 clinical trial, pembrolizumab showed superior clinical outcomes to platinum‐based chemotherapy in patients with metastatic NSCLC exhibiting positive PD‐L1 expression (TPS ≥ 1%).8